Fate Therapeutics (FATE) Change in Accured Expenses (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Change in Accured Expenses data on file, last reported at -$5.8 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 41.24% year-over-year to -$5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.0 million (up 28.72% YoY) and the FY2025 annual result came in at -$9.0 million, down 443.47% from the prior year.
• Change in Accured Expenses fell to -$5.8 million in Q1 2026, from $865000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $10.3 million in Q3 2022 to a low of -$20.4 million in Q1 2023.
• A 5-year average of -$1.8 million and a median of -$550000.0 in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses tumbled 483.82% — and 2024, when it soared 182.03%.
• Tracing FATE's Change in Accured Expenses over 5 years: stood at $3.4 million in 2022, then sank by 155.89% to -$1.9 million in 2023, then surged by 134.6% to $655000.0 in 2024, then jumped by 32.06% to $865000.0 in 2025, then tumbled by 767.51% to -$5.8 million in 2026.
• The last three Change in Accured Expenses figures came in at -$5.8 million (Q1 2026), $865000.0 (Q4 2025), and -$550000.0 (Q3 2025), per Business Quant data.